Menu
Search
|

Menu

Close
X

Celgene Corp CELG.OQ (NASDAQ Stock Exchange Global Select Market)

95.26 USD
-0.88 (-0.92%)
As of Feb 16
chart
Previous Close 96.14
Open 96.01
Volume 1,967,351
3m Avg Volume 2,733,736
Today’s High 96.79
Today’s Low 95.25
52 Week High 147.13
52 Week Low 88.34
Shares Outstanding (mil) 782.35
Market Capitalization (mil) 108,911.00
Forward P/E 43.29
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.10 Mean rating from 31 analysts

KEY STATS

Revenue (mm, USD)
FY17
12,998
FY16
11,229
FY15
9,256
EPS (USD)
FY17
5.216
FY16
2.486
FY15
1.937
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
43.29
32.90
Price to Sales (TTM)
vs sector
8.93
5.77
Price to Book (MRQ)
vs sector
12.89
5.41
Price to Cash Flow (TTM)
vs sector
31.48
23.42
Total Debt to Equity (MRQ)
vs sector
169.13
16.52
LT Debt to Equity (MRQ)
vs sector
163.21
12.22
Return on Investment (TTM)
vs sector
10.08
14.43
Return on Equity (TTM)
vs sector
37.19
16.13

EXECUTIVE LEADERSHIP

Mark Alles
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $1,062,580.00
Bonus: $3,689,650.00
Scott Smith
President, Chief Operating Officer, Since 2017
Salary: $691,667.00
Bonus: $1,296,830.00
Peter Kellogg
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $845,667.00
Bonus: $2,707,910.00
Terrie Curran
President, Global Inflammation & Immunology Franchise, Since 2017
Salary: --
Bonus: --
Michael Pehl
President, Hematology & Oncology, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

86 Morris Ave
SUMMIT   NJ   07901-3915

Phone: +1908.6739000

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

SPONSORED STORIES